Tango Therapeutics, Inc. (TNGX), headquartered in Cambridge, Massachusetts, is devoted to unraveling cancer's complexity and overcoming its resistance to treatment. This biotechnology company specializes in pioneering the discovery, development, and commercialization of innovative medicines that can improve and potentially prolong the lives of people suffering from cancer. Tango Therapeutics is driven by its purpose of altering the paradigm of cancer therapies to revolutionize patient care.
Founded in 2017 by leading scientists from renowned science and research entities, the company is primarily focused on creating medicines that exploit cancer's vulnerabilities. Tango Therapeutics' uniqueness lies in its proprietary research platform that leverages advances in DNA sequencing and CRISPR-based functional genomics to uncover genetically validated therapeutic targets.
Through this platform, the company aims to create superior, more precise, and individualized treatments for patients with a variety of cancer types. The company has meticulously integrated drug discovery capabilities to help accelerate the development and launch of their first program into clinical trials.
Tango Therapeutics is presently focused on developing targeted therapies for patients suffering from genetically defined cancers. They maintain a patient-centric approach, leaning on genetic data to design treatments that maximize effectiveness and minimize side effects. Their pipeline includes potential solutions for various types of cancer, including BRCA-1 breast cancer, CDK12 prostate cancer, and others still in the early phases of discovery and development.
Tango is unique due to its “synthetic lethality” method, a technique that detects and utilizes the interactions between pairs of genes in which the defect or disorder in one gene is harmless unless a corresponding defect occurs in the other gene. This approach offers the potential for targeted cancer therapies that could outperform traditional methods.
Tango Therapeutics' pioneering work in synthetic lethality and genetic vulnerabilities has attracted significant interest and support from high-profile institutional investors and industry partners. It's financed by Third Rock Ventures, Boxer Capital, and Casdin Capital, among others.
Tango Therapeutics, Inc. exemplifies how the integration of cutting-edge technology and a deep understanding of genomics can produce pioneering remedies to some of the most challenging health problems. With a mission built on science, innovation, and determination, this young biotech company shows immense promise in ushering in a new era of personalized cancer treatment.